Back to FeedIntel Vault / Permanent Record
[ARCHIVE]2026-07-01T12:02:39.202158+00:00
Acute respiratory distress syndrome patients improve with experimental monoclonal antibody treatment

Acute respiratory distress syndrome patients improve with experimental monoclonal antibody treatment

Executive Summary

Doctors have few options for patients who develop a life-threatening lung condition called acute respiratory distress syndrome, or ARDS. A frequent cause of death during the COVID-19 pandemic, ARDS occurs when an inflammatory cascade triggered by infection or injury leaks fluid into the lungs, crash...

Deep analysis unavailable for this source.

View Original SourceClassification: Open